Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra, is now available.

March 3, 2009 — On February 26, sanofi-aventis announced that a prefilled disposable pen containing insulin glulisine (Apidra SoloSTAR) was approved by the US Food and Drug Administration (FDA ...

Apidra(R) can be administered using an insulin pump, vial and syringe, the OptiClik(R) reusable insulin delivery device, the Apidra(R) SoloSTAR(R) prefilled disposable insulin pen or intravenously ...

Sanofi-aventis has won FDA approval for Apidra SoloSTAR, a prefilled disposable pen, for children with type 1 diabetes and adults with type 1 or 2 diabetes. Apidra, which has been on the market in ...

French pharmaceutical manufacturer Sanofi recently notified doctors that they will soon face a shortage of an insulin pen product. The manufacturing incident occurred on July 11, according to ...

Sanofi-Aventis <SASY.PA> has won U.S. approval to market its Apidra Solostar injection pen which contains insulin to treat diabetes, the world's third-biggest drugmaker said on Thursday.

Sanofi is also cutting the list price of its short-acting Apidra insulin by 70%. ... for up to two boxes of pens for a 30-day supply. Other manufacturers cut prices, too.

In the meantime, the company recommends that doctors consider switching patients to Apidra vials and syringes. The product currently on the market is safe, the letter says. - here's the letter (.pdf) ...

The Lantus SoloStar insulin pen will be affected by the new labeling requirements. The FDA is taking action to ensure that multidose insulin pens do not spread diseases by requiring the injectable ...

The FDA has approved Apidra SoloSTAR (insulin glulisine [rDNA origin] injection, from sanofi-aventis), a prefilled disposable pen containing Apidra.